United States Biosimilar Market Size Projected to Reach USD 33.2 Billion by 2034 with a CAGR of 17.60%

IMARC Group has recently released a new research study titled “United States Biosimilar Market Report by Molecule, Manufacturing Type, Indication, and Region, 2026-2034,” offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

United States Biosimilar Market Size, Growth, and Forecast (2026-2034)

The united states biosimilar market size grew from USD 7.7 Billion in 2025 to USD 9.1 Billion in 2026, and is projected to reach USD 33.2 Billion by 2034, growing at a CAGR of 17.60% during 2026-2034. Rising demand for affordable treatments for chronic diseases such as cancer and diabetes, increasing efforts to reduce healthcare costs, and supportive FDA policy reforms are the primary factors driving the us biosimilars market.

Biosimilars are biologic medical products that are highly similar to, and have no clinically meaningful differences from, an existing FDA-approved reference biologic. With comparable efficacy and safety at significantly reduced prices, biosimilars are increasingly adopted as a cost-saving alternative across the U.S. healthcare system, particularly as high-revenue biologics continue to face patent expirations.

According to a 2024 research report by the National Center for Chronic Disease Prevention and Health Promotion, about 129 million Americans have one or more major chronic conditions, with chronic diseases accounting for 90% of the annual USD 4.1 trillion U.S. healthcare costs. This growing disease burden, combined with policy reforms such as the Biosimilar User Fee Act (BsUFA) that streamline regulatory pathways, continues to strengthen the united states biosimilar market outlook.

Analyze the United States Biosimilar Market - Download the IMARC Sample Report for Insights: https://www.imarcgroup.com/united-states-biosimilar-market/requestsample

Key Trends Driving the United States Biosimilar Market

• Expansion of biosimilar treatment categories: Biosimilar manufacturers are diversifying their portfolios beyond oncology and autoimmune diseases into rare diseases, ophthalmology, and hormonal therapies. Among the biosimilars market trends 2026, the FDA's approval of Langlara (insulin glargine-aldy), an interchangeable biosimilar to Lantus, on April 29, 2026, for adults and pediatric patients with type 1 diabetes and adults with type 2 diabetes, reflects this continued expansion into complex, high-need therapeutic areas.
• Increasing focus on biosimilar substitution policies: Many states are adopting laws and guidelines allowing pharmacy-level substitution of biosimilars for reference biologics, while insurers are revising formularies to promote biosimilar use. In March 2026, the FDA announced new draft guidance introducing streamlined pharmacokinetic study requirements for monoclonal antibody biosimilars, a change estimated to reduce developer costs by up to 50%, further accelerating market entry.
• Strategic partnerships and co-development initiatives: Collaborations between biosimilar manufacturers and established pharmaceutical companies are becoming increasingly prevalent, enabling smaller firms to leverage larger companies' expertise, distribution networks, and resources. On January 10, 2025, Samsung Bioepis and Teva formed a collaboration to develop, seek regulatory approval, and commercialize EPYSQLI (eculizumab-aagh), a biosimilar of Soliris, in the U.S.

United States Biosimilar Market Report Segmentation:

The United States Biosimilar Market report provides a detailed segmentation analysis to help businesses identify key growth segments and evolving industry dynamics. The market is categorized based on molecule, manufacturing type, indication, and region, offering comprehensive insights across the us biosimilars market.

Molecule Insights:

• Infliximab: Infliximab biosimilars hold a major share, driven by widespread use across autoimmune disease treatment, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
• Insulin Glargine: Insulin glargine biosimilars play an important role in managing the growing diabetes population, offering a more affordable alternative to long-acting branded insulins.
• Epoetin Alfa: Epoetin alfa biosimilars are used to treat anemia related to chronic kidney disease and cancer, valued for cost-effectiveness combined with therapeutic equivalence.
• Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa: These molecules continue to see steady adoption across autoimmune, oncology, growth deficiency, and fertility treatment applications.
• Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab: These high-revenue biologic classes are seeing accelerated biosimilar competition following recent patent expirations.
• Others: Other molecules include emerging biosimilar candidates targeting rare diseases and specialized indications.

Manufacturing Type Insights:

• In-house Manufacturing: In-house manufacturing allows companies greater control over quality, costs, and timelines, ensuring regulatory compliance and intellectual property security for complex biologics.
• Contract Manufacturing: Contract manufacturing is growing as biosimilar developers outsource production to specialized third parties, reducing infrastructure investment while accelerating time-to-market.

Indication Insights:

• Auto-Immune Diseases: Auto-immune diseases hold a major share of the market, with biosimilars targeting infliximab and adalimumab reducing treatment costs for conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease.
• Blood Disorder: Blood disorder biosimilars, including epoetin alfa and filgrastim, are revolutionizing treatment for anemia and neutropenia.
• Diabetes: The diabetes segment is growing rapidly as insulin glargine biosimilars gain market acceptance amid rising diabetes rates across the U.S.
• Oncology: Oncology biosimilars, including trastuzumab and bevacizumab, are expanding access to cancer treatment as branded biologics face growing competition.
• Growth Deficiency: Growth deficiency treatments benefit from somatropin biosimilars, offering more affordable options for pediatric and adult growth hormone therapy.
• Female Infertility: Female infertility treatments are increasingly supported by follitropin alfa biosimilars, improving access to fertility care.
• Others: Other indications include emerging applications across rare diseases and specialized hormonal therapies.

Regional Insights:

On the question of which regions will lead biosimilars market growth in 2026, the Northeast currently leads adoption, though the South and West are emerging as key growth contributors.

• Northeast: The Northeast leads in biosimilar adoption due to its advanced healthcare infrastructure, concentration of specialized medical facilities, and strong awareness among healthcare professionals in states including New York and Massachusetts.
• Midwest: The Midwest is showing steady growth, supported by expanded access to low-cost healthcare and rising chronic disease prevalence in states such as Illinois and Ohio.
• South: The South is one of the most rapidly growing regional markets, driven by a large and diversified population and increasing chronic disease incidence in states including Texas and Florida.
• West: The West is a significant contributor, with states such as California leading in innovation, regulatory advancements, and proximity to biotechnology hubs.

United States Biosimilar Market: Recent News and Developments

• March 2026: The FDA announced new draft guidance introducing streamlined pharmacokinetic study requirements for monoclonal antibody biosimilars, an initiative estimated to reduce developer costs by up to 50%, or approximately USD 20 Million per program.
• April 29, 2026: The FDA approved Langlara (insulin glargine-aldy), an interchangeable biosimilar to Lantus, for adults and pediatric patients with type 1 diabetes and adults with type 2 diabetes, expanding affordable treatment options for the diabetes population.

Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=11073&flag=C

Challenges Impacting the United States Biosimilar Market

Despite FDA-approved biosimilars being as safe and effective as branded drugs, their market share remains below 20% of eligible biologic prescriptions, reflecting persistent gaps in physician and patient confidence. Building trust through education remains an ongoing challenge for manufacturers and healthcare providers alike.

Complex manufacturing requirements and high development costs for biosimilars, particularly for monoclonal antibodies, continue to create barriers to entry for smaller companies. Regulatory fragmentation around interchangeability designations and state-level substitution laws also adds complexity for manufacturers seeking nationwide distribution and pharmacy-level adoption.

Investment Opportunities in the United States Biosimilar Market

The united states biosimilar market presents compelling investment opportunities supported by its projected growth from USD 9.1 Billion in 2026 to USD 33.2 Billion by 2034. Expansion into underserved therapeutic areas such as rare diseases, ophthalmology, and complex monoclonal antibodies represents a high-value opportunity as manufacturing technology continues to advance.

Strategic partnerships and co-development agreements between biosimilar developers and established pharmaceutical companies offer an additional avenue for investment, allowing companies to share development costs, reduce regulatory risk, and accelerate commercialization in this expanding us biosimilars market.

Outlook of the United States Biosimilar Market (2026-2034)

The outlook for the united states biosimilar market is positive, supported by the rising prevalence of chronic diseases, continued patent expirations for high-revenue biologics, and streamlined FDA regulatory pathways. The market is projected to grow from USD 9.1 Billion in 2026 to USD 33.2 Billion by 2034 at a CAGR of 17.60%.

Continued expansion of biosimilar substitution policies, growing physician and patient education initiatives, and ongoing strategic collaborations between manufacturers will be among the key biosimilars market trends 2026 and beyond shaping the united states biosimilar market through 2034.

Key Players in the United States Biosimilar Market

The united states biosimilar market features strong pharmaceutical companies investing substantially in R&D to develop high-quality biosimilars meeting stringent regulatory standards, while pursuing collaborations and aggressive pricing strategies to expand market share.

• Sandoz International GmbH: A global leader in the biosimilars space, Sandoz has expanded its U.S. portfolio through acquisitions such as CIMERLI, a ranibizumab biosimilar for ophthalmology, strengthening its position across multiple therapeutic areas.
• Amgen, Inc.: A major U.S. biopharmaceutical company, Amgen manufactures biosimilars including Bkemv (eculizumab-aeeb), the first interchangeable biosimilar approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Frequently Asked Questions (FAQs): United States Biosimilar Market

1. What is the current United States biosimilar market size?

The United States biosimilar market grew from USD 7.7 Billion in 2025 to USD 9.1 Billion in 2026, and is projected to reach USD 33.2 Billion by 2034, growing at a CAGR of 17.60% during 2026-2034.

2. What is a biosimilar?

A biosimilar is a biologic medical product that is highly similar to, and has no clinically meaningful differences from, an existing FDA-approved reference biologic, offering comparable efficacy and safety at a reduced cost.

3. What are the key drivers of the us biosimilars market?

Key drivers include the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, increasing efforts to reduce healthcare costs, patent expirations for high-revenue biologics, and supportive FDA regulatory reforms.

4. Which regions will lead biosimilars market growth in 2026?

The Northeast currently leads biosimilar adoption due to its advanced healthcare infrastructure, while the South and West are emerging as the fastest-growing regions, driven by large diversified populations and expanding biotechnology hubs.

5. Who are the key players in the United States biosimilar market?

Key players in the united states biosimilar market include Sandoz International GmbH, Pfizer Inc., Teva Pharmaceutical Industries Limited, Celltrion Inc., Biocon Biologics Ltd, Samsung Biologics, Amgen Inc., Dr. Reddy's Laboratories Limited, Fresenius Kabi USA, and Chugai Pharmaceutical Co., Ltd., among others.

Author IMARC Group

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

United States: +1-201971-6302